{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=17", "query": { "condition": "Cancer, Advanced", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 9813, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T07:16:56.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05634577", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adrenocortical Carcinoma" ], "interventions": [ { "name": "Mitotane", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-03-23", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634577" }, { "nct_id": "NCT06921928", "title": "Study for AZD4360 in Participants With Advanced Solid Tumours", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD4360", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 31, "start_date": "2025-04-29", "completion_date": "2027-12-16", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 3, "location_summary": "Santa Monica, California • Providence, Rhode Island • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06921928" }, { "nct_id": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "NAI + Pembrolizumab", "type": "DRUG" }, { "name": "NAI + Nivolumab + Ipilimumab", "type": "DRUG" }, { "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-05-18", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 31, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520686" }, { "nct_id": "NCT00257205", "title": "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "dacarbazine", "type": "DRUG" }, { "name": "CP-675,206", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 655, "start_date": "2006-03", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2012-07-02", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 55, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00257205" }, { "nct_id": "NCT04404595", "title": "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "CT041", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CARsgen Therapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 110, "start_date": "2020-10-23", "completion_date": "2035-09-01", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04404595" }, { "nct_id": "NCT02942095", "title": "Study of Ixazomib and Erlotinib in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-03-06", "completion_date": "2022-12-07", "has_results": false, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02942095" }, { "nct_id": "NCT00513695", "title": "Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammatory Breast Cancer", "Male Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2007-06", "completion_date": "2017-10-16", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 7, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Boise, Idaho + 3 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Boise", "state": "Idaho" }, { "city": "Mount Vernon", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513695" }, { "nct_id": "NCT05366166", "title": "Pembrolizumab Plus Olaparib in LA-HNSCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "IMRT (intensity modulated radiation therapy)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2022-09-02", "completion_date": "2030-11-21", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Louisville, Kentucky • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05366166" }, { "nct_id": "NCT00369629", "title": "Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-08-28", "completion_date": "2013-06-04", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369629" }, { "nct_id": "NCT03114319", "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)", "KRAS G12-mutant NSCLC", "Esophageal Squamous Cell Cancer (SCC)", "Head/Neck SCC", "Melanoma", "Advanced Gastrointestinal Stromal Tumors (GIST)", "Advanced NRAS/BRAFT wt Cutaneous Melanoma" ], "interventions": [ { "name": "TNO155", "type": "DRUG" }, { "name": "TNO155 in combination with EGF816 (nazartinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 227, "start_date": "2017-05-26", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-07T07:16:56.424Z", "location_count": 4, "location_summary": "Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03114319" } ] }